Biocon confident of meeting $200-million revenue guidance target for biologics segment

“We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.

from Moneycontrol Business News https://ift.tt/2OTFpzy